AbbVie Inc. $ABBV Shares Acquired by Aviva PLC

Aviva PLC boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 8.0% in the second quarter, HoldingsChannel reports. The firm owned 1,322,515 shares of the company’s stock after purchasing an additional 98,463 shares during the period. AbbVie comprises about 0.5% of Aviva PLC’s portfolio, making the stock its 28th largest holding. Aviva PLC’s holdings in AbbVie were worth $245,485,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie during the 2nd quarter valued at approximately $25,000. TD Capital Management LLC increased its stake in shares of AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after buying an additional 58 shares during the last quarter. Spurstone Advisory Services LLC acquired a new stake in AbbVie in the second quarter valued at $28,000. Cypress Capital Management LLC WY bought a new position in AbbVie during the 1st quarter valued at $35,000. Finally, Bear Mountain Capital Inc. boosted its stake in AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after acquiring an additional 173 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the sale, the executive vice president directly owned 177,292 shares in the company, valued at $35,178,278.64. This trade represents a 19.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.25% of the stock is currently owned by company insiders.

AbbVie Stock Down 0.1%

Shares of AbbVie stock opened at $218.92 on Friday. The stock has a market capitalization of $386.74 billion, a price-to-earnings ratio of 104.25, a PEG ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a twelve month low of $163.81 and a twelve month high of $244.81. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The business’s 50 day simple moving average is $223.24 and its 200-day simple moving average is $202.30.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is currently 524.24%.

Wall Street Analyst Weigh In

ABBV has been the subject of several research analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Bank of America lifted their price target on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Wall Street Zen upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Finally, DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $236.57.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.